Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis

Tsubasa Tsutsumi^{1

2}, Takumi Kawaguchi³, Hideki Fujii⁴, Yoshihiro Kamada⁵, Yuichiro Suzuki⁶, Koji Sawada⁷, Miwa Tatsuta⁸, Tatsuji Maeshiro⁹, Hiroshi Tobita¹⁰, Takemi Akahane¹¹, Chitomi Hasebe¹², Miwa Kawanaka¹³, Takaomi Kessoku^{14

15

16}, Yuichiro Eguchi¹⁷, Hayashi Syokita¹⁸, Atsushi Nakajima¹⁶, Tomoari Kamada¹³, Hitoshi Yoshiji¹¹, Hiroshi Sakugawa¹⁹, Asahiro Morishita²⁰, Tsutomu Masaki²⁰, Takumi Ohmura²¹, Toshio Watanabe⁵, Yoshioki Yoda²², Nobuyuki Enomoto⁶, Masafumi Ono²⁰, Kanako Fuyama²³, Kazufumi Okada²³, Naoki Nishimoto²³, Yoichi M Ito²³, Hirokazu Takahashi²⁴, Michael R Charlton²⁵, Mary E Rinella²⁵, Yoshio Sumida²⁶

Affiliations

¹ Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, 5841 South Maryland Ave., Chicago, IL, 60637, USA. tsubasa@uchicagomedicine.org.
² Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan. tsubasa@uchicagomedicine.org.
³ Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
⁴ Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahimachi, Abeno, Osaka, 545-8585, Japan.
⁵ Department of Advanced Metabolic Hepatology, Osaka University Graduate School of Medicine, 1-7, Yamadaoka, Suita, Osaka, 565-0871, Japan.
⁶ First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, 1110, Shimokato, Chuo-Shi, Yamanashi, 409-3898, Japan.
⁷ Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka Higashi, Asahikawa-City, Hokkaido, 078-8510, Japan.
⁸ Department of Gastroenterology, KKR Takamatsu Hospital, 4-18 Tenjinmae, Takamatsu, Kagawa, 760-0018, Japan.
⁹ First Department of Internal Medicine, University of the Ryukyus Hospital, 207 Uehara, Nishihara, Nakagami, Okinawa, 903-0215, Japan.
¹⁰ Department of Hepatology, Shimane University Hospital, 89-1 Enya-Cho, Izumo, Shimane, 693-8501, Japan.
¹¹ Department of Gastroenterology, Uda City Hospital, 815 Haibarahagihara, Uda, Nara, 633-0253, Japan.
¹² Department of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Akebono-1Jo 1Chome 1-1, Asahikawa-City, Hokkaido, 070-0061, Japan.
¹³ Department of General Internal Medicine 2, Kawasaki Medical School, Kawasaki Medical Center, 2-6-1, Nakayamashimo, Kita, Okayama, 700-8505, Japan.
¹⁴ Kanagawa Dental University Yokohama Clinic, Yokohama, Kanagawa, Japan.
¹⁵ Department of Palliative Medicine and Gastroenterology, International University Health and Welfare Narita Hospital, 4-3, Kimizunomori 4-Chome, Narita-Shi, Chiba, 286-8686, Japan.
¹⁶ Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
¹⁷ Loco Medical General Institute, Mikatsukicho Kanada, Ogi-Shi, Saga, 845-0032, Japan.
¹⁸ Department of Gastroenterology, Northern OKINAWA Medical Center, 1712-3 Umusa, Nago, Okinawa, 905-0006, Japan.
¹⁹ Department of Gastroenterology, Heartlife Hospital, 208, Iju, Nakagusuku, Nakagami, Okinawa, 901-2492, Japan.
²⁰ Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Oaza Ikenobe Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
²¹ Department of Health Care, Asahikawa-Kosei General Hospital, 24-111, 1 Jo-Dori, Asahikawa-City, Hokkaido, 078-8211, Japan.
²² JA Yamanashi Koseiren Health Care Center, 1-26, Iida 1, Kofu, Yamanashi, 400-0035, Japan.
²³ Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, 060-8648, Japan.
²⁴ Liver Center, Saga University Hospital, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
²⁵ Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, 5841 South Maryland Ave., Chicago, IL, 60637, USA.
²⁶ Graduate School of Healthcare Management, International University of Healthcare and Welfare, 4-1-26, Akasaka, Minato-Ku, Tokyo, Japan.

PMID: 40097845
DOI: 10.1007/s00535-025-02242-y

Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis

Tsubasa Tsutsumi et al. J Gastroenterol. 2025 Jul.

. 2025 Jul;60(7):891-904.

doi: 10.1007/s00535-025-02242-y. Epub 2025 Mar 18.

Authors

Affiliations

¹ Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, 5841 South Maryland Ave., Chicago, IL, 60637, USA. tsubasa@uchicagomedicine.org.
² Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan. tsubasa@uchicagomedicine.org.
³ Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
⁴ Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahimachi, Abeno, Osaka, 545-8585, Japan.
⁵ Department of Advanced Metabolic Hepatology, Osaka University Graduate School of Medicine, 1-7, Yamadaoka, Suita, Osaka, 565-0871, Japan.
⁶ First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, 1110, Shimokato, Chuo-Shi, Yamanashi, 409-3898, Japan.
⁷ Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka Higashi, Asahikawa-City, Hokkaido, 078-8510, Japan.
⁸ Department of Gastroenterology, KKR Takamatsu Hospital, 4-18 Tenjinmae, Takamatsu, Kagawa, 760-0018, Japan.
⁹ First Department of Internal Medicine, University of the Ryukyus Hospital, 207 Uehara, Nishihara, Nakagami, Okinawa, 903-0215, Japan.
¹⁰ Department of Hepatology, Shimane University Hospital, 89-1 Enya-Cho, Izumo, Shimane, 693-8501, Japan.
¹¹ Department of Gastroenterology, Uda City Hospital, 815 Haibarahagihara, Uda, Nara, 633-0253, Japan.
¹² Department of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Akebono-1Jo 1Chome 1-1, Asahikawa-City, Hokkaido, 070-0061, Japan.
¹³ Department of General Internal Medicine 2, Kawasaki Medical School, Kawasaki Medical Center, 2-6-1, Nakayamashimo, Kita, Okayama, 700-8505, Japan.
¹⁴ Kanagawa Dental University Yokohama Clinic, Yokohama, Kanagawa, Japan.
¹⁵ Department of Palliative Medicine and Gastroenterology, International University Health and Welfare Narita Hospital, 4-3, Kimizunomori 4-Chome, Narita-Shi, Chiba, 286-8686, Japan.
¹⁶ Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
¹⁷ Loco Medical General Institute, Mikatsukicho Kanada, Ogi-Shi, Saga, 845-0032, Japan.
¹⁸ Department of Gastroenterology, Northern OKINAWA Medical Center, 1712-3 Umusa, Nago, Okinawa, 905-0006, Japan.
¹⁹ Department of Gastroenterology, Heartlife Hospital, 208, Iju, Nakagusuku, Nakagami, Okinawa, 901-2492, Japan.
²⁰ Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Oaza Ikenobe Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
²¹ Department of Health Care, Asahikawa-Kosei General Hospital, 24-111, 1 Jo-Dori, Asahikawa-City, Hokkaido, 078-8211, Japan.
²² JA Yamanashi Koseiren Health Care Center, 1-26, Iida 1, Kofu, Yamanashi, 400-0035, Japan.
²³ Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, 060-8648, Japan.
²⁴ Liver Center, Saga University Hospital, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
²⁵ Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, 5841 South Maryland Ave., Chicago, IL, 60637, USA.
²⁶ Graduate School of Healthcare Management, International University of Healthcare and Welfare, 4-1-26, Akasaka, Minato-Ku, Tokyo, Japan.

PMID: 40097845
DOI: 10.1007/s00535-025-02242-y

Abstract

Background: Individuals with metabolic-associated steatotic liver disease (MASLD) have a worse prognosis compared to patients without steatosis, and its prevalence is increasing. However, detailed risk factors based on obesity and sex remain unclear. We aimed to investigate the impact of cardiometabolic risk factors (CMRFs) on the risk of MASLD in individuals without pre-existing SLD.

Methods: SLD was diagnosed by ultrasonography. Non-SLD individuals were followed 65,657 person-years. Incidence rates of MASLD were assessed by Kaplan-Meier analysis. Furthermore, independent factors associated with the development of MASLD were identified using Cox regression analysis, stratified by four groups: obese men, non-obese men, obese women, and non-obese women.

Results: The overall incidence rate of MASLD was 39.3/1,000 person-years. The cumulative incidence was highest in obese men, followed by obese women, non-obese men, and non-obese women. Two or more CMRFs increased the risk of MASLD in all groups. Low HDL cholesterol level was the strongest independent risk factor in both obese and non-obese women and hypertriglyceridemia for both obese and non-obese men. The impact of these CMRFs was stronger in non-obese individuals. (HR [95% CI]: women non-obese 1.9 [1.5-2.4], obese 1.4 [1.1-1.8]; men non-obese 2.3 [1.9-2.9], obese 1.5 [1.2-2.0]).

Conclusions: Multiple CMRFs are important to MASLD development, regardless of sex and obesity. In this Japanese cohort, low HDL cholesterol in women and hypertriglyceridemia in men were the most significant risk factors, especially among the non-obese group. These findings suggest that sex-specific CMRFs may play a role in the development of MASLD.

Keywords: Cardiometabolic risk factors; Hypertriglyceridemia; Low HDL cholesterol levels; Metabolic dysfunction-associated steatotic liver disease (MASLD); Steatotic liver disease.

PubMed Disclaimer

Conflict of interest statement

Declaration. Conflict of interest: T.K. received lecture fees from Janssen Pharmaceutical K.K., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., ASKA Pharmaceutical Co., Ltd., AbbVie GK., EA Pharma Co., Ltd. M.K. received a research grant from Fuji Rebio. A.N. received honorariums from EA Pharma Co., Ltd, Mochida Pharmaceutical Co., LTD., Kowa Company, Ltd., Taisho Pharmaceutical Co., Ltd., and Viatris; a fee from EA Pharma Co., Ltd.; and a research grant from EA Pharma Co., Ltd, Mochida Pharmaceutical Co., LTD., Kowa Company, Ltd., and Gilead Science. H.Y. received lecture fees from Otsuka Pharmaceutical Co., Ltd., Asuka Pharmaceutical Co., Ltd., Gilead Sciences, Novel Pharmaceutical, Taisho Pharmaceutical Co., Ltd., and AbbVie Inc. H.T. received lecture fees from Novonordisk, Kowa Company, Ltd., and Taisho Pharmaceutical Co., Ltd., and a fee for writing from an undisclosed company. M.E.R. provides scientific consulting for Akero, 89Bio, Boehringer Ingelheim, Intercept Pharmaceuticals, Histoindex, Madrigal, NGM Biopharmaceuticals, Novo Nordisk, Eli Lilly, Sagimet Biosciences, Sonic Incytes, Cytodyn, and GSK and serves on the scientific executive boards of Akero, Madrigal, and Novo Nordisk. M.R.C. is employed by Madrigal and previously provided scientific consulting for Novo Nordisk, 89Bio, Northsea, Merck, Akero, Cytodyn, Pfizer, Aligos, Sagimet, and Eli Lilly. Y.Su. received a research grant from an undisclosed company and scholarship grants from Takeda and Sysmex. The other authors have no conflicts of interest relevant to this publication.

References

1. Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2024. https://doi.org/10.3350/cmh.2024.0431 . - DOI - PubMed - PMC
1. Le MH, Yeo YH, Zou B, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022;28:841–50. - PubMed - PMC - DOI
1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5. - PubMed - DOI
1. Li L, Liu DW, Yan HY, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016;17:510–9. - PubMed - DOI
1. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862–73. - PubMed - DOI

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

Startup Award for Researchers with Life Events/Kurume University

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis

Affiliations

Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis

Authors

Affiliations

Abstract

Conflict of interest statement

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical